1 / 28

Overview of Investor Relations Capabilities

Overview of Investor Relations Capabilities. Rx COMMUNICATIONS. Specialists in the life science and healthcare industries Partner-driven -- Senior level counsel on EVERY account Partners have been through up and down market cycles, various political healthcare agendas and technology trends.

mahola
Download Presentation

Overview of Investor Relations Capabilities

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Overview of Investor Relations Capabilities

  2. Rx COMMUNICATIONS • Specialists in the life science and healthcare industries • Partner-driven -- Senior level counsel on EVERY account • Partners have been through up and down market cycles, various political healthcare agendas and technology trends

  3. Rx COMMUNICATIONS • Experience with private and public companies – domestic and international • Focused on what we do best: Investor Relations and Financial Media Relations • Strong Wall Street and media contacts • Headquartered in New York City

  4. PRIVATE COMPANIES Services for Private Companies

  5. WHY EMBARK ON AN IR/PR PROGRAM AS A PRIVATE COMPANY? • Lay the groundwork for future financings and eventual IPO • Assist with partnering activities by building corporate awareness • Build awareness of disease indications to generate product interest • Align company with reputable bankers • Become accustomed to working within disclosure rules i.e.; Reg FD

  6. PROVIDING VALUE TO PRIVATE COMPANIES • Develop key messages positioned for analysts and investors • Develop collateral materials to tell story integrating key messages • Target and facilitate introductions to venture capitalists and institutional investors • Target and advise on corporate finance team • Target and facilitate introductions to sell-side analysts

  7. PROVIDING VALUE TO PRIVATE COMPANIES • Build presence on the web • Develop story ideas for the media • Cultivate reporter interest • Introduce to conference circuit • Properly position company news • Develop company disclosure policy

  8. ACTIVITIES SUROUNDING IPO • Assist in the selection of banking team – beginning of quiet period • Press release announcing registration for offering • Develop roadshow presentation • Supplement banker’s list of target institutions • Presentation training

  9. ACTIVITIES SURROUNDING IPO • “Teach-ins” at banks • Roadshow • Press release announcing completion of IPO • “Welcome letter” to new shareholders • Create disclosure policy • Quiet period lasts for 25 days following the close of IPO

  10. PUBLIC COMPANIES Services for Public Companies

  11. AFTER-MARKET SUPPORT • Need for continual dialogue with shareholders • On-going targeting of investors for future financings • Increase analyst coverage beyond banking support • Fulfill disclosure requirements • Crisis communications • Strategic media out-reach

  12. GETTING STARTED: FIRST STEPS • Strategy session in order to immerse ourselves in corporate story • Define key message points • Understand perceptions existent in the marketplace • Create targeted list of sell-side analysts, venture capitalists and fund managers

  13. GETTING STARTED: FIRST STEPS • Review collateral materials • Create VIP blast e-mail/fax lists • Develop media lists • Design action plan

  14. Rx COMMUNICATIONS CAPABILITIES • Strategic Counsel • Roadshows • Analyst Contact • Investor Targeting • Investment and Industry Conferences • Follow-up and Analysis to Key Events • Press Release Writing • News Conferences/Press Briefings • Video/Radio News Releases • Fact Sheets • Annual Reports

  15. Rx COMMUNICATIONS CAPABILITIES • Crisis Communications • Mergers and Acquisitions • Positioning Strategy • Perception Audits • Conference Calls • Presentation Training • Placement Strategy • Financial, Trade and Local Media Contacts • Slide Presentations • Web Site Development

  16. THE Rx TEAM Melody A. Carey, Co-President • Founded Rx in 2000 • Head of Corporate Communications and Spokesperson, Schein Pharmaceutical, Inc. • Director of Investor Relations, The Multicare Companies, Inc. • Executive, Noonan/Russo Communications • Former healthcare/life sciences investment banker, Kidder, Peabody & Co.

  17. THE Rx TEAM Rhonda Chiger, Co-President • Founded Rx in 2000 • Senior Managing Director, Global Consulting Practice, Thomson Financial • Managed Life Sciences departments for Noonan/Russo and Dewe Rogerson • Established London office for healthcare investor relations firm • Former Manager, Investor Relations, American Stock Exchange

  18. The Rx Team Eric Goldman, Vice President • 25 years experience in public relations and as a media relations strategist specializing in biotechnology, healthcare, technology and consumer products • Senior Director and Vice President at GlobalFluency • Handled media relations at Spector & Associates and Brouillard Communications, a division of J. Walter Thompson • Earned 2 Silver Anvil awards for public relations excellence

  19. THE Rx TEAM Paula B. Schwartz, Senior Vice President • Former Partner, FRB/Weber Shandwick, oldest and largest Investor Relations firm in the U.S. • Former Vice President, ECOM Consultants, Inc., an investor relations firm • Former Vice President/Director of Investor Relations Programs, KCS&A Public Relations, a public relations and investor relations consultancy

  20. Rx COMMUNICATIONS CURRENT CLIENT LIST • ADMA Biologics, Inc. (Private) • Alexandria Real Estate Equities, Inc. (NYSE: ARE) • Alexion Pharmaceuticals Inc. (Nasdaq: ALXN) • Bio-Path Holdings, Inc. (OTCQX: BPTH) • Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) • Complix NV (Private) • Galena Biopharma, Inc. (Nasdaq: GALE) • Intact Medical Corporation (Private)

  21. Rx COMMUNICATIONS CURRENT CLIENT LIST • MAXIMUS, Inc. (NYSE: MMS) • MolMedS.p.A. (Milan: MLM) • Neovacs, SA (Alternext Paris: ALNEV) • Omthera Pharmaceuticals, Inc. (Private) • PDI, Inc. (Nasdaq: PDII) • TetraLogic Pharmaceuticals (Private) • Theratechnologies (TSX: TH)

  22. OURx SUCCESSES Helped to grow Alexion Pharmaceuticals’ institutional shareholder base from 30% in 1996 to approximately 95% today. Launched not-for-profit Immune Tolerance Institute resulting in broad coverage in the U.S. including CBS Radio Network, San Francisco Business Times and Drug Discovery News Garnered coverage for Catalyst Pharmaceutical Partners’ compound for cocaine addiction. Placements included cover stories in Newsweek, Scientific American Mind and NeuroInvestment

  23. OURx SUCCESSES Designed and implemented IR program for American CareSource Holdings which led the company to be ranked as the number one stock performer on The NASDAQ Capital Market for 2008. An aggressive investor outreach campaign on behalf of Genaissance Pharmaceuticals allowed Genaissance to regain compliance with Nasdaq’s $1 listing rule requirement. Guided Kos Pharmaceuticals through a failed marketing alliance which caused over two million shares to trade (four times the average daily trading volume) and the stock never dropped below 2%.

  24. OURx SUCCESSES Arranged feature coverage focused on Hodgkins and non-Hodgkins lymphoma for MethylGene with Genetic Engineering News, Pink Sheet, BioCentury and Pharmawire Guided ABIOMED on issues management surrounding FDA panel meeting. Put FDA’s request for additional data into perspective with reporters and investors. CNBC interview key part of strategy. Implemented aggressive IR program for PharmAthene, Inc. which enabled the company to obtain coverage from two new sell-side analysts, garner investments from four new institutional funds and increase trading volume by three-fold within nine months.

  25. OURx SUCCESSES Rx Communications was named Best Small PR Agency byLeague of American Communications Professionals We are pleased to announce that Rx Communications has been selected by PR Week as a finalist for Boutique PR Agency of the Year Rx Communications Group was honored with the 2008 Stevie Award for Best Investor Relations Program for work on behalf of specialty pharmaceutical company, NexMed, Inc.

  26. OURx SUCCESSES We are also pleased to share that our work for ImpactRx has won an Honorable Mention Award in LACP’s (League of American Communications Professionals) 2002 Publicity Campaign Competition. Rx Communications was honored with the 2002 SABRE Awards Certificate of Excellence for Building a North American Investor Base for client Syngenta AG. Rx Communications received an honorable Mention Award from PR News, as part of the PR News Platinum PR Awards 2003. The award was issued in the Financial/Investor Relations category, for the company's work on behalf of Genaissance Pharmaceuticals, Inc.

  27. WHY Rx COMMUNICATIONS? • Specialist industry knowledge and expertise • Personal attention from Rx partners • Decades of experience in strategic counsel and implementation of financial public relations programs • Unique niche in working with private companies • Well versed in IPOs, secondary offerings, PIPEs, venture rounds and mergers and acquisitions • “The Street” knows and trusts us

  28. For Additional Information: Rx Communications Group, LLC 445 Park Avenue 10th Floor New York, NY 10022 (917) 322-2568 www.RxIR.com

More Related